Tags

Type your tag names separated by a space and hit enter

Coxsackievirus A16: epidemiology, diagnosis, and vaccine.
Hum Vaccin Immunother. 2014; 10(2):360-7.HV

Abstract

Coxsackievirus 16 (CA16) is one of the major pathogens associated with hand, foot, and mouth disease (HFMD) in infants and young children. In recent years, CA16 and human enterovirus 71 (EV71) have often circulated alternatively or together in the Western Pacific region, which has become an important public health problem in this region. HFMD caused by CA16 infection is generally thought to be mild and self-limiting. However, recently several severe and fatal cases involving CA16 have been reported. Studies have shown that co-infection with CA16 and EV71 can cause serious complications in the central nervous system (CNS) and increase the chance of genetic recombination, which may be responsible for the large HFMD outbreak in Mainland China in 2008. For these reasons, recent studies have focused on the virological characteristics of CA16 and the development of CA16-related diagnostic reagents and vaccines.

Authors+Show Affiliations

National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.National Institutes for Food and Drug Control; Beijing, PR China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24231751

Citation

Mao, Qunying, et al. "Coxsackievirus A16: Epidemiology, Diagnosis, and Vaccine." Human Vaccines & Immunotherapeutics, vol. 10, no. 2, 2014, pp. 360-7.
Mao Q, Wang Y, Yao X, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360-7.
Mao, Q., Wang, Y., Yao, X., Bian, L., Wu, X., Xu, M., & Liang, Z. (2014). Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Human Vaccines & Immunotherapeutics, 10(2), 360-7. https://doi.org/10.4161/hv.27087
Mao Q, et al. Coxsackievirus A16: Epidemiology, Diagnosis, and Vaccine. Hum Vaccin Immunother. 2014;10(2):360-7. PubMed PMID: 24231751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coxsackievirus A16: epidemiology, diagnosis, and vaccine. AU - Mao,Qunying, AU - Wang,Yiping, AU - Yao,Xin, AU - Bian,Lianlian, AU - Wu,Xing, AU - Xu,Miao, AU - Liang,Zhenglun, Y1 - 2013/11/14/ PY - 2013/11/16/entrez PY - 2013/11/16/pubmed PY - 2015/1/6/medline KW - Coxsackievirus A16 (CA16) KW - animal model KW - neutralizing antibody KW - recombination KW - vaccine SP - 360 EP - 7 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 10 IS - 2 N2 - Coxsackievirus 16 (CA16) is one of the major pathogens associated with hand, foot, and mouth disease (HFMD) in infants and young children. In recent years, CA16 and human enterovirus 71 (EV71) have often circulated alternatively or together in the Western Pacific region, which has become an important public health problem in this region. HFMD caused by CA16 infection is generally thought to be mild and self-limiting. However, recently several severe and fatal cases involving CA16 have been reported. Studies have shown that co-infection with CA16 and EV71 can cause serious complications in the central nervous system (CNS) and increase the chance of genetic recombination, which may be responsible for the large HFMD outbreak in Mainland China in 2008. For these reasons, recent studies have focused on the virological characteristics of CA16 and the development of CA16-related diagnostic reagents and vaccines. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/24231751/Coxsackievirus_A16:_epidemiology_diagnosis_and_vaccine_ L2 - https://www.tandfonline.com/doi/full/10.4161/hv.27087 DB - PRIME DP - Unbound Medicine ER -